Drug Profile
Research programme: monoclonal antibody therapeutics - Quark Pharmaceuticals
Alternative Names: PAb-W4Latest Information Update: 07 Sep 2010
Price :
$50
*
At a glance
- Originator Quark Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Renal failure
Most Recent Events
- 10 Aug 2007 Preclinical trials in Renal failure in USA (Parenteral)